Merck, SCC420, B16-OVA MO4 Mouse Melanoma Cell Line

General description
The immune system can recognize and destroy tumors. Cytotoxic T lymphocytes (CTLs) kill neoplastic (or virally infected) cells after recognizing antigenic peptides bound to major histocompatibility complex (MHC) class I molecules on their surface. These peptides are derived from antigens that are degraded in the cytosol of the affected cell. Immunizations with killedpathogens or their proteins do not generally elicit CTLs, because exogenous proteins cannot enter the cytosol (to bepresented). However, antigens that are internalized into phagocytic cells can enter the cytosol and be processed for classI presentation. Immunization with a purified antigen attached to an avidly phagocytized particle primes CTLs, which in turnprotect animals from subsequent challenge with tumors transfected with the antigen gene.
Application
Each vial contains >1X106 viable cells.
Cells are tested negative for infectious diseases by a Mouse Essential CLEAR panel by Charles River Animal Diagnostic Services.

Cells are verified to be of mouse origin and negative for inter-species contamination from rat, Chinese hamster, Golden Syrian hamster, human and non-human primate (NHP) as assessed by a Contamination CLEAR panel by Charles River Animal Diagnostic Services.
Cells are negative for mycoplasma contamination.

Background
The immune system can recognize and destroy tumors. Cytotoxic T lymphocytes (CTLs) kill neoplastic or virally infected cells after recognizing antigenic peptides bound to major histocompatibility complex class I molecules on their surface. These peptides are derived from antigens that are degraded in the cytosol of the affected cell. Immunizations with killed pathogens or their proteins do not generally elicit CTLs, because exogenous proteins cannot enter the cytosol (to be presented). However, antigens that are internalized into phagocytic cells can enter the cytosol and be processed for class I presentation. Immunization with a purified antigen attached to an avidly phagocytized particle primes CTLs, which in turn protect animals from subsequent challenge with tumors transfected with the antigen gene.1

Source
Tumor rejection antigens – TRAs – differ from any other protein synthesized by the cell in that the host is intolerant to them. Thus virtually any foreign protein synthesized by a tumor, including those expressed from foreign antigen genes transfected into tumor cells, should function and behave like TRAs. This hypothesis was tested in a murine tumor model developed by transfecting the chicken ovalbumin gene into the C57BL/6 (H-2b haplotype)-derived murine melanoma cell line B16, followed by selection and isolation of the ovalbumin (OVA)-transfected B16 clone B16-OVA MO4.1
In in vitro challenge, B16-OVA MO4 cells stimulated the OVA+ Kb-specific T-cell hybridoma RF33.70 to produce interleukin-2 whereas untransfected B16 cells did not. Injected intradermally into syngeneic C57Bl/6 mice, both B16 and B16-OVA MO4 grew progressively, metastasized, and killed the animals showing that expression of the ovalbumin antigen alone does not render this tumor sufficiently immunogenic to be rejected. Subcutaneous immunization of C57Bl/6 mice with ovalbumin conjugated to iron beads (OVA-Fe), however, protected B16-OVA MO4 (but not B16) challenged animals both from local tumor growth and death. This approach could be exploited to develop tumor and viral vaccines.1

References
1. Falo LD Jr, Kovacsovics-Bankowski M, Thompson K, Rock KL. Nat. Med. 1995; 1(7):649-653.
2. Fidler IJ. Cancer Res. 1975; 35(1):218-224.

Note: Mouse xenotropic retrovirus Bxv-1 proviral DNA is detected in B16-OVA MO4 cells, BXV-1 is a Biosafety Level 2 (BSL-2) pathogen.
Features and Benefits
B16-OVA MO4 cell line is a model for cancer immunotherapy, expressing ovalbumin (OVA) in order to facilitate strong immune responses to tumor antigens.
Preparation Note
Cells should be stored in liquid nitrogen until use. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.
Other Notes
Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/restrictedcelluse. This product may not be: re-engineered or copied; used to make derivatives, modifications or functional equivalents; used to obtain patents or other IP claiming use of the product; used to develop, test, or manufacturer a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact [email protected].
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.